Arvinas Secures $70M in Series C Funding to Accelerate Next-Generation Protein Degrader Therapies

Arvinas, a pioneering clinical-stage biotechnology company, is thrilled to announce that it has successfully raised $70,000,000 in its latest funding round. This significant investment highlights the strong belief of investors in Arvinas’ revolutionary approach to treating debilitating and life-threatening diseases. Using its cutting-edge PROTAC Discovery Engine, Arvinas is at the forefront of engineering proteolysis targeting chimeras—innovative molecules designed to leverage the body’s natural protein disposal system to selectively and efficiently eliminate disease-causing proteins. With this new capital infusion, Arvinas aims to accelerate its mission to transform patient care across several therapeutic areas. The funding will be strategically allocated to advancing multiple investigational drugs currently in clinical development. Key programs include vepdegestrant, a promising candidate targeting the estrogen receptor for patients battling locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, designed to address relapsed or refractory non-Hodgkin Lymphoma by targeting the BCL6 protein; and ARV-102, which focuses on neurodegenerative disorders by targeting the LRRK2 protein. Based in New Haven, CT—a vibrant biotech hub—Arvinas combines scientific rigor with innovative technology to improve the lives of patients worldwide. This fundraising milestone not only reinforces the company’s financial stability but also underscores its commitment to breakthrough research and the development of novel therapies that could potentially redefine treatment paradigms for serious illnesses. As Arvinas moves forward with its clinical programs, the biotech community and patients alike have every reason to be optimistic about the future of precision medicine and targeted protein degradation as game-changing therapeutic strategies. For more information about the company and its groundbreaking work, please visit www.arvinas.com.